STOCKS TELEGRAPH

Author: ST Staff

  • On What Basis Did DarioHealth (DRIO) Stock Rise In Extended Trades?

    On What Basis Did DarioHealth (DRIO) Stock Rise In Extended Trades?

    The pioneer in the global digital therapeutics market, DarioHealth Corp. (DRIO) shares ended after-hours trading at $17.26 up 6.87%. At the close of business last session, DRIO stock increased 1.25% or $0.2 to $16.15. Over the course of the day, DarioHealth stock fluctuated between $15.70 and $16.43. In the regular session, DRIO shares changed hands for 0.19 million, lower than the 0.3 million volume for the 50 days prior and lower than its 0.28 million Year to Date volume.

    DRIO stock has fallen 133.72% in the past 12 months, and it has fallen -16.67% in the last week. DRIO has lost -18.31% in the last six months and has lost -2.24% in the last three months. So far this year, shares have returned 13.02%. As a regional healthcare organization selected DRIO as a digital health provider, DRIO stock continued to rise.

    What made them choose DRIO?

    DarioHealth is a leading company in digital therapeutics that is revolutionizing the way chronic-ill patients manage their medical conditions. Digital therapeutics solutions from DRIOS are among the most comprehensive on the market – supporting the treatment of multiple chronic conditions, including diabetes, hypertension, weight management, musculoskeletal health, and behavioral health. A unique user-centric approach to product design and engagement makes DRIO products stand out from the competition and deliver results that customers can depend on.

    Alabama Regional Medical Services (ARMS) selected DarioHealth as a digital health provider, announced DRIO in a press release yesterday.

    • ARMS is a Federally Qualified Health Center (FQHC) in Jefferson, Shelby, St. Clair, and Blount counties, which is accredited by The Joint Commission as a Primary Care Medical Home.
    • In regard to managing hypertension among a diverse patient population, including many underserved and uninsured individuals, ARMS selected DRIO’s Remote Patient Monitoring (RPM).
    • The percentage of Alabamans with high blood pressure is over 40%, and those who live in lower-income neighborhoods tend to suffer worse outcomes.
    • By partnering with DRIO, ARMS has access to innovative technologies and highly personalized support that engage patients, including those who have challenges utilizing technology.
    • The contract represents DRIO’s second competitive win in the last month for its RPM division.

    How is DRIO going to support ARMS?

    With the DarioHealth (DRIO) RPM system, ARMS joins a growing number of providers and health systems that are seeking to address the stubborn challenge of engaging patients in improving their health and wellbeing. A key reason for ARMS’ selection of DRIO was its ability to customize its RPM solution to meet the unique clinical and financial goals of the organization while helping to meet the unique needs of the population.

  • What Caused The SNBR Stock To Drop In Afterhours Session?

    What Caused The SNBR Stock To Drop In Afterhours Session?

    The stock price of Sleep Number Corporation (SNBR) dropped 10.91% in after-hours trading Tuesday at $99.99. At the close of a regular trading session, SNBR shares had gained 5.42% to conclude at $112.24. SNBR stock price ranged was between $106.64 and $113.38.

    A total of 1.02 million shares were traded for SNBR, which was above the daily average of 0.49 million shares over 100 days. Last month, SNBR shares gained 10.70%, while they gained 0.36% in the last five days. Following the release of its quarterly results, SNBR stock declined.

    How did SNBR perform last quarter?

    In Sleep Number, individuality is a guiding principle. The SNBR team comprises over 5,000 highly motivated individuals, each of whom is dedicated to improving lives by enhancing the sleep experience through personalization. By enhancing the quality of sleep, SNBR is improving the lives of over 13 million people and contributing to society’s wellbeing.

    A science-based approach to design is behind SNBR’s award-winning 360 smart beds. Through the accumulation of nearly 11 billion hours of near-perfect, real-world sleep data, they learn from over a billion sleep sessions to provide effortless comfort and excellent sleep to every sleeper. SleepIQ scores, 24/7 sleep health reports, and other sleep health insights are all part of the 360 smart bed by SNBR and contribute to the advancement of sleep health solutions.

    Results for the quarter ended July 3 were reported by Sleep Number Corporation yesterday.

    Financial Highlights:

    • SNBR’s net sales were up 39% year-to-date versus last year to $1.05 billion and 35% versus the first half of this 2019.
    • Sales per SNBR store were over $3.5 million over the trailing twelve months (ttm) as supply constraints limited deliveries during the second quarter.
    • SNBR’s gross profit increased by 39% year-to-date to $649 million, or 61.6% of net sales, in comparison to the 61.4% profit in 2020 and 61.3% profit in 2019.
    • Year to date, SNBR has posted an operating income of $106 million, an increase of 161% which was 10.1% of sales; this is an increase of 5.4% from 2020 and 5.1% from 2019.
    • With the year-to-date earnings per diluted share increasing 270%, SNBR’s earnings per share recorded a record $3.44, compared with $0.93 in 2020 and $0.95 in 2019.
    • SNBR generated $161 million in net cash from operating activities for the first half of 2021, up 86% from last year and 129% higher than in the first half of 2019.
    • During the first six months of 2021, the company spent $32 million on capital expenditures and invested $267 million in SNBR stock.
    • At the end of the second quarter, SNBR’s leverage ratio was 2.2x EBITDAR, down from 2.8x a year prior, and below its longer-term target of 2.5x-3.0x.
    • The return on invested capital (ROIC) at SNBR increased by 17.2% for the comparable period to more than 33% for the ttm period.

    Financial Outlook by SNBR:

    Sleep Number (SNBR) raised its earnings per diluted share outlook for 2021 to at least $7.25, which represents a 58% increase over 2020. For the remainder of the year, SNBR anticipates that the effective income tax rate will be 25%. In 2021, SNBR intends to generate more than $300 million in operating cash flow with roughly $75 million in capital expenditures.

  • What Motivated The EGLX Stock To Continue The Rally After Hours?

    What Motivated The EGLX Stock To Continue The Rally After Hours?

    In after-hours trading, shares of media and content platform for video game and esports fans to connect and engage, Enthusiast Gaming Holdings Inc. (EGLX) were trading at $5.35, up 6.57% from the close. Gaming enthusiast stock ended Tuesday’s session up 8.42% at $5.02. Within the past 50 days, EGLX’s average daily volume has been 0.84 million shares, which is higher than the volume of 0.58 million shares traded on the day.

    Since the beginning of the year, the share price of EGLX has gained 332.76%, and in the past week, the price has risen by 4.37%. EGLX stock has fallen -41.90% over the past three months, and -9.23% during the past six months. Moreover, EGLX currently has a market capitalization of $626.34 million with 124.77 million outstanding shares. A new board appointment continued to drive EGLX stock higher in extended trading following the regular session.

    Who has been appointed by EGLX?

    Enthusiast Gaming builds the largest platform of video game and esports content available for connecting and engaging users worldwide. EGLX offers an integrated approach to reach and interact with the coveted GenZ and Millennial audience by combining the elements of its four core pillars of Media, Talent, Esports, and Experiences. In addition to providing a vast network of like-minded communities, EGLX’s proprietary mix of digital media and entertainment assets enables it to tailor the content and experience to the audience.

    Mr. John Albright was announced yesterday as the newest member of the Board of Directors and Audit Committee at Enthusiast Gaming. John is the Managing Partner and Co-Founder of Relay Ventures, a venture capital firm that invests in North American startups and growth enterprises.

    A Toronto-based venture capital firm founded in 2008, Relay Ventures has a significant presence in San Francisco as well. John has shaped the visions and capital plans of countless entrepreneurs for long-term, sustainable growth throughout his career. In finance, he has spent several years as a venture capitalist and private equity investor and has helped entrepreneurs obtain seed funding through IPOs and M&A advisory.

    Why is the new appointment important for EGLX?

    John Albright’s additional involvement on the Board of Directors will benefit EGLX as it strives to become the world’s largest platform for gamers and esports enthusiasts. As a business leader with extensive experience in scaling businesses, John brings to Enthusiast Gaming (EGLX) a wide range of skills in the area of media, technology, innovation, and gambling. Having a passion for what EGLX is building gives John a unique perspective that will be crucial for guiding EGLX toward its growth objectives.

  • NeuroMetrix, Inc. (NURO) Stock Soars Following Breakthrough Designation for Quell Device

    NeuroMetrix, Inc. (NURO) Stock Soars Following Breakthrough Designation for Quell Device

    NeuroMetrix, Inc. (NURO) stock prices skyrocketed by 145.51% some time after market trading commenced on July 20th, 2021, bringing the price per share up to USD$8.00 early on in the trading day.

    Breakthrough Designation Granted

    July 20th, 2021 saw the company announce that the United States Food and Drug Administration granted Breakthrough Designation for NURO’s Quell device, which is designed to treat symptoms of fibromyalgia in adults. With the company reporting moving forward with regulatory filing, it hopes to launch Quell for fibromyalgia indication by the second half of 2021.

    Fibromyalgia

    Fibromyalgia is a form of chronic pain that is associated with fatigue, sleep, cognitive, and mood disturbances. With nearly 2 to 6% of the population of the U.S being affected, diagnoses are most often made between the ages of 30 and 50. While the cause of the illness is unclear, studies have indicated abnormalities in the way the brain processes normal sensations and pain. Despite the FDA having approved several drugs for the management of fibromyalgia pain, there is still a significant unmet need for safe and effective non-pharmacological treatments.

    Quell Technology

    Quell is an innovative, non-invasive, nerve stimulation device that is designed to mitigate the effects of fibromyalgia. Covered by 18 U.S utility patents, it sets itself apart as the only wearable neurostimulator that functions with the use of a custom designed microchip. The device provides flexible, accurate, high-power nerve stimulation in a form factor not bigger than a credit card. The device uses position and motion sensing to automatically adjust stimulation output for an optimal patient experience over the course of the entire day. Bluetooth low energy is supported by the device in communication with its app, which is available on both Android and Apple mobile devices.

    Breakthrough Device Designation

    The FDA Breakthrough Device Program is designed to facilitate the accessibility of breakthrough technologies for the patients that need them urgently. As per the program, the FDA will provide a priority review for NeuroMetrix, as well as interactive communication regarding its development. Furthermore, government policies and programs currently in the works have the potential to facilitate Medicare reimbursement for FDA Breakthrough Devices after they have been granted marketing authorization.

    Future Outlook for NURO

    Armed with the support of the FDA, NURO is poised to capitalize on the massive market space it finds at its disposal. Current and potential investors are hopeful for the accelerated development and commercialization of Quell so as to maximize gains in shareholder value.

  • LSB Industries, Inc. (LXU) Stock Soars Following Exchange Agreement with LSB Funding LLC

    LSB Industries, Inc. (LXU) Stock Soars Following Exchange Agreement with LSB Funding LLC

    LSB Industries, Inc. (LXU) stock prices were up a massive 31.98% some time after market trading commenced on July 20th, 2021, bringing the price per share up to USD$6.48 early on in the trading day.

    Agreement with LSB Funding

    July 20th, 2021 saw the company announce the signing of a definitive agreement with LSB Funding LLC, an affiliate of Eldridge. The agreement will see shares of LSB Series E-1 and Series F-1 being exchanged for shares of LXU common stock. As per the agreement, the closing of the transaction will see LXU exchange roughly USD$300 million worth of preferred stock that is held by Eldridge into the equivalent value of LXU common stock. The exchange has been priced at USD$6.16 per share, which is equal to the 30-day volume-weighted average price as of the date of the agreement. Furthermore, LXU shareholders as of the record date will be granted a special dividend in the form of 0.30 shares of LXU for each share owned.

    Advancing the Partnership

    The closing of the transaction will result in the elimination of the company’s current financial impact and repayment of accrued compounding preferred stock and future accruing dividends at 14.5%. This number is set to increase to 16% in April 2023, with the move continuing to unburden the company, thereby unlocking shareholder value

    LXU’s Expanded Scope

    The Special Committee, Board of Directors, and company management are confident that the transaction has the potential to lead to an upgrade in its rating, thereby allowing LXU to refinance its senior secures notes at a lower interest rate and on improved terms. This, in turn, will facilitate a reduction of the cash interest expense and overall cost of capital for the company.

    Benefits of the Collaboration

    The transaction also serves to improve the company’s financial flexibility, allowing it to allocate resources towards organic growth initiatives, including, but not limited to, growth in green ammonia and clean energy and accretive M&A opportunities. Furthermore, the company will see its substantial tax attributes be preserved, including roughly USD$620 million of federal net operating losses. This facilitates the protection of prospective significant future cash savings and shareholder value.

    Future Outlook for LXU

    Armed with a highly promising collaboration, the company is poised to capitalize on the massively expanded scope of business it finds at its disposal. Current and potential investors are hopeful that management will be able to leverage their resources to facilitate a continued trajectory of success and growth in equity value.

  • Immunome, Inc. (IMNM) Stock Skyrockets Following Promising Results of IMM-BCP-01 in Neutralizing Delta Variant of Covid-19

    Immunome, Inc. (IMNM) Stock Skyrockets Following Promising Results of IMM-BCP-01 in Neutralizing Delta Variant of Covid-19

    Immunome, Inc. (IMNM) stock prices soared by 20.85% shortly after market trading commenced on July 20th, 2021, bringing the price per share up to USD$20.11 early on in the trading day.

    IMM-BCP-01

    July 20th, 2021 saw the company announced the potent neutralizing activity demonstrated by its three-antibody cocktail (IMM-BCP-01) against the Delta variant of the coronavirus pandemic. The treatment also showed in-vitro activity via non-neutralizing mechanics, such as complement fixation, which the company anticipates enabling viral clearance for the treatment.

    Addressing Delta Variant Concerns

    With the highly concerning evolution of the Covid-19 virus taking the world by storm, the company is hopeful that its drug candidate is adequately positioned to become a leader in the global fight against the deadly coronavirus. The treatment’s ability to maintain neutralizing activity against the newer Covid-19 variants is highly promising, with its mechanisms of action targeting at least three non-overlapping epitopes. The mechanisms are informed by an authentic human immune response and provide a robust defense against future mutational drift.

    Expediting Development

    With the majority of the current cases in the United States reporting infection with the Delta variant of the coronavirus, the company was awarded USD$17.6 million as a technology award to aid the development of the treatment. Granted by the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense in collaboration with the Defense Health Agency, the award serves to accelerate the availability of the treatment as the world hurtles towards universal immunizations.

    Ahead of the Curve

    With cases finally dwindling down, the United States is on high alert for the near-term potential for a resurgence of coronavirus infections, as a result of the emerging variants. The company is exploring all options to expedite the development of IMM-BCP-01, with plans to submit an IND application with the U.S Food and Drug Administration as early as this quarter. The biopharmaceutical company leverages its proprietary human memory B cell platform in a bit to aid the discovery and development of first-in-class antibody therapeutics.

    Future Outlook for IMNM

    Armed with a promising drug candidate that could address the massive gap that arose in the marketspace as a result of the proliferation of the Delta variant, IMNM is poised to capitalize on the expanded scope of the opportunities afforded to it. Investors are hopeful that management will be able to spearhead the commercialization and proliferation of IMM-BCP-01, thus resulting in increases in shareholder value over the long term.

  • Infobird Co., Ltd. (IFBD) Stock Surges Following Successful Launch of Intelligent SaaS Solution for Leading Client

    Infobird Co., Ltd. (IFBD) Stock Surges Following Successful Launch of Intelligent SaaS Solution for Leading Client

    Infobird Co., Ltd. (IFBD) stock prices were up by 8.49% shortly after market trading commenced on July 20th 2021, bringing the price per share up to USD$3.45 early on in the trading day.

    IFBD’s SaaS Product

    July 20th 2021 saw the company announce the successful implementation of its proprietary Intelligent Quality Inspection SaaS with a leading Chinese Fintech company. The SaaS product has facilitated the realization of intelligent management and operation by IFBD’s client’s customer service platform. The Intelligent Quality Inspection SaaS also serves as the basis for further upgrading of the client’s customer service.

    Intelligent Quality Inspection

    The company has persisted in promoting the implementation of intelligent quality inspection across a myriad of market sectors over the past few years, serving to facilitate the expansion of the scope of application of intelligent quality inspection. Since its inception, Intelligent Quality Inspection has catered to financial, e-commerce, retail, and other industries. The standardized intelligent SaaS product will give clients the ability to better track the engagement between the company and its end customers.

    Scope of IFBD’s Solution

    With a range of applicability in so many sectors, the solution is essential for the financial industry on account of its very high compliance and service requirements for customer and sales centers. The company’s success in serving its Fintech client with Intelligent Quality Inspection will serve as the track record that will bolster IFBD’s foray into the financial industry.

    Advantages of IQI

    The partnering Fintech company prioritizes customer service, while constantly seeking to elevate the quality of management and customer service it offers. This is facilitated by various methods, including, but not limited to, quality inspection and training. The adoption of the Intelligent Quality Inspection system has seen the advancement from manual inspections by random sampling to automatic inspection with 100% coverage. This results in the obsolescence of quality inspectors with the achievement of 100% inspections serving to comprehensively improve management efficiency. With such complete coverage, the company negates the risk of product or service defects slipping through the cracks of selective, random inspections.

    Future Outlook for IFBD

    Armed with the successful implementation of its leading SaaS product, IFBD is poised to capitalize on the expanded scope of opportunities it finds at its disposal as a result of its partnership. Investors are hopeful that the success of this collaboration will pave the way for the company to expand its network of clients, ushering in significant and sustained increases in shareholder value over the long term.

  • Aldeyra (ALDX): What Is Driving The Stock Higher?

    Aldeyra (ALDX): What Is Driving The Stock Higher?

    Aldeyra Therapeutics Inc. (ALDX) is rising today on the charts, trading up 2.18% to $9.39 per share at the last check in early trading. Aldeyra stock has raised nearly 12% in the premarket session today. As of Monday, Aldeyra shares closed at $9.19, down 3.47% on day. The total volume traded in ALDX stock was 1.01 million shares, less than the 1.47 million average traded volumes over the past three months. The ALDX stock fluctuated between $8.52 and $9.7299 during the trading session.

    The earnings ratio for ALDX was -1.02. On a yearly basis, ALDX stock has gained 33.97% and lost 10.97% in the past five sessions. In the previous month, ALDX stock moved -24.36 percent. Currently, the 50-day moving average for ALDX stock is $11.56, which is above the 200-day moving average of $10.18. Furthermore, ALDX stock price is trading at an RSI of 24.28.

    ALDX stock is soaring since it received Orphan Drug Designation from the US Food and Drug Administration (FDA) for one of its products.

    Which ALDX drug received the designation?

    Aldeyra is a biotechnology company focused on the development of immunomodulating therapies for the treatment of ocular and systemic ailments. ALDX’s two lead product candidates, reproxalap and ADX-629, target RASPs (reactive aldehyde species), which are cytokine pre-cycling molecules that cause inflammation. Phase 3 clinical trials of Reproxalap are being conducted at ALDX in patients with dry eyes and allergies. ADX-2191 (methotrexate for intravitreal injection) is another potential drug candidate in ALDX’s clinical pipeline.

    In a press release today, Aldeyra announced that the FDA has granted the company orphan drug designation for its ADX-2191 drug candidate for the treatment of primary vitreoretinal lymphoma (PVRL).

    • The PVRL, a rare, aggressive, high-grade cancer that is diagnosed annually in approximately 600 US patients, has currently no approved treatment.
    • By Designating ADX-2191 as an orphan drug, the FDA opens the way for clinical trials and commercialization for the drug.
    • Additionally, this designation represents the first formulation of methotrexate specifically designed for intraocular use, giving ALDX a competitive advantage.
    • ALDX retinal disease program has taken another step forward with this designation, supporting it in its ongoing development of ADX-2191 to prevent proliferative vitreoretinopathy, which is the primary cause of retinal reattachment failure.

    Will this benefit ALDX?

    As an orphan drug developer, Aldeyra (ALDX) would qualify for federal financial incentives, as the program allows the same for pharmaceuticals and biologics for treating rare diseases. In consideration of its orphan drug designation, ALDX is also eligible to receive tax credits for its clinical trial costs, waivers of user fees for marketing applications, and consideration for seven years of marketing exclusivity, if approved.

  • EnzoBiochem Inc. (ENZ) stock surged in the premarket trading session; here’s why

    EnzoBiochem Inc. (ENZ) stock surged in the premarket trading session; here’s why

    EnzoBiochem Inc. (ENZ stock) saw its shares surge in the premarket trading session by 8.74% to $3.36 at last check. ENZ stock previously closed the session at $3.07. The ENZ stock volume traded 200,900 shares, lower than the average daily volume of 0.432 million shares that were traded within the past 50 days. In the past year up to date, ENZ shares have jumped by 16.73% and in the past week, they have plunged by -3.15%. In the past three and six months, the ENZ stock has shed -5.54%, while adding 0.99%. Furthermore, ENZ stock is currently valued in the market at $151.69 million and has 48.39 million outstanding shares.

    The operational background of EnzoBiochem Inc.

    EnzoBiochem Inc. is often referred to as a biotech company which is technically incorrect since it specifically is a Diagnostics & Research company. ENZ stock focuses on the development, manufacturing, integration of the market, and research diagnostics for products. These diagnostics are based on biotechnology, genetic engineering, and molecular biology. The company operates through three segments which are Products, Clinical Services, and Therapeutics.

    The Products segment creates, makes, and markets items and devices to clinical examination, drug improvement, and bioscience research clients. It offers proteins, antibodies, peptides, little particles, marking tests, colors, and packs, which give life science specialists instruments to target ID/approval, content examination, quality articulation investigation, nucleic corrosive discovery, protein organic chemistry, and location, and cell examination. The logical specialists that are working in this segment focus on the fields of malignant growth, cardiovascular sickness, neurological problems, diabetes and weight, endocrine issues, and immune system illness, hepatotoxicity, and renal injury.

    The Clinical Services fragment gives standard and elusive clinical research center tests or strategies utilized in everyday patient consideration by doctors to set up or support a conclusion, screen treatment or medicine, or quest for a generally undiscovered condition.

    The Therapeutics portion creates novel methodologies in the space of gastrointestinal, irresistible, ophthalmic, and metabolic infections.

    ENZ stock is made a reputation for its immediate salesforce, distribution network, and channel, as well as the large client base it has gathered in the United States and internationally. EnzoBiochem, Inc. was established in 1976 and is settled in New York, New York.

    Emergency Use Authorization given by FDA for ENZ stock’s rapid extraction method for detection of SARS-CoV-2

    Since the advent of the COVID-19 many biotech and research-based companies have created their own proprietary services, products and systems to deal with the detection, vaccination, and recovery from SARS-CoV-2. Similarly, ENZO stock has also launched its own proprietary system that helps detect coronavirus. Enzo’s quicker extraction measure decreases recognition time by more than 60 minutes, or over 25%, empowering more trials on a solitary instrument. The fast extraction technique can be utilized on stages including Enzo’s exclusive GENFLEX® computerized high-throughput stage, Qiagen’sQIAsymphony® SP lower-throughput stage and Enzo’s manual work process. The AMPIPROBE® SARS-Cov-2 Test System incorporates three segments: test assortment, AMPIXTRACT™ SARS-CoV-2 Extraction Kit for test preparing, and AMPIPROBE® SARS-CoV-2 Assay Kit for identification and examination.

    This was all done thanks to the expansion of the FDA’s Emergency Use Authorization (EUA) for the rapid testing system. This comes in great need now since the world is now witnessing the 4th wave of Coronavirus which brings along with it a proliferation of new variants and complexities.

  • Why Standard Lithium Ltd. (SLI) stock is Popping High in Current Market today?

    Why Standard Lithium Ltd. (SLI) stock is Popping High in Current Market today?

    Standard Lithium Ltd. (SLI) stock announced the appointment of Dr. Volker Berl to the board of directors after which the SLI stock price popped high by 15.16% to reach $5.47 a share as of this writing. The trading volume for today at the time of this writing was 1,278,671. SLI stock was down by 7.77% at the previous closing. Let’s deep dive to explore more of it.

    What’s Happening?

    Standard Lithium Ltd is engaged in the development and processing of lithium brine properties in the United States of America. The stock today reported that it has appointed Dr. Volker Berl as an independent director of Standard Lithium Ltd. Berl is an experienced professional having deep knowledge of the chemical industry and profound experience in institutional capital markets. He is the founder and Chief Executive Officer of New Age Ventures.

    As a result of the appointment, Standard Lithium granted 22,500 performance share units, 7,500 restricted share units, and 200,000 incentive stock options to Dr. Volker Berl. The PSUs will be vested after achieving the performance milestones as described in the SLI’s news release of January 18, 2021. The RSUs will be vested quarterly in four equal parts in a time period of twelve months. The first part will be vested on September 30, 2021. The options will be vested immediately and exercisable till July 19, 2026, at an exercise price of $6.08.

    Previous Activity by SLI stock:

    On July 15, 2021, SLI stock did announce that it has delivered its ‘SiFT’ lithium carbonate plant to the El Dorado Arkansas project site. The site is located at LANXESS South Plant facility. Several truck-loads of the modular plant had been sent to the site. It was also reported that the installation team will install a weatherproof structure on the site and then it can or will be hydraulically integrated.

    Wrap Up:

    Investors are responding positively to the recent announcement by SLI stock related to the appointment of Dr. Volker Berl. The stock has a market cap of 675.502 million and the average trading volume is 421,037. In a nutshell, it is much better to analyze fundamentals as well as future growth before adding this stock to the portfolio.